Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care
5.8% of patients receiving CAR T-cell therapy developed second primary malignancies (SPMs), with hematologic malignancies, solid tumors, and nonmelanoma skin cancers being the most common subtypes. SPM risk factors include treatment setting, follow-up duration, and previous treatment lines.
Reference News
Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care
5.8% of patients receiving CAR T-cell therapy developed second primary malignancies (SPMs), with hematologic malignancies, solid tumors, and nonmelanoma skin cancers being the most common subtypes. SPM risk factors include treatment setting, follow-up duration, and previous treatment lines.